ArticleBMC psychiatry2025
Efficacy of paliperidone palmitate once-monthly (PP1M) in improving social functioning and reducing caregiver burden in patients with schizophrenia: a six-month follow-up study.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundSchizophrenia is a complex chronic mental disorder that severely impairs patients' social functioning and quality of life, while imposing substantial burdens on families and society. Long-acting injectable antipsychotics (LAIs) have demonstrated potential advantages in improving both symptoms and social functioning. This study investigated the effects of transitioning from oral antipsychotics (OAPS) to Paliperidone Palmitate Once-Monthly (PP1M) on symptom control, social functioning, and caregiver burden in schizophrenia patients.
methodsFrom April 11 to October 31, 2024, participants were assessed monthly using the Positive and Negative Syndrome Scale-6 (PANSS-6), Brief Psychiatric Rating Scale (BPRS), and adverse effect records. The Zarit Caregiver Burden Inventory and Personal and Social Performance (PSP) scale were administered biannually.
resultsAmong 95 patients completing 6-month PP1M treatment, Zarit Burden scores decreased significantly by 44.89% (p < 0.001), while PSP scores increased by 8.60% (p = 0.001). Both PANSS-6 and BPRS total scores showed significant reductions (p < 0.00238). A moderate negative correlation was observed between BPRS improvement and PSP enhancement (r = -0.535, p < 0.001).
conclusionPP1M treatment effectively controlled symptoms, improved social functioning, and reduced caregiver burden in schizophrenia patients. The significant correlation between symptom improvement and functional recovery suggests PP1M may substantially support long-term rehabilitation and quality of life enhancement.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.